Arquer Diagnostics Announces New Distribution Agreements for Poland & Saudi Arabia Markets

Arquer Diagnostics Ltd (“Arquer”), a UK-based company focusing on the development of non-invasive cancer diagnostic tests today announced two strategic commercial partnerships with BIOKOM Diagnostyka and Al-Hobail Medical Office, who will take over the distribution of Arquer products across Poland and Saudi Arabia, respectively.

These new distributor appointments mean that Arquer Diagnostic products including the innovative ADXBLADDER non-invasive urine test for bladder cancer can be accessed within additional European and Middle-Eastern markets. ADXBLADDER is currently commercialised in UK, France, Italy, Turkey and the Nordic region and will be further released to other European countries and worldwide regions in 2018.

BIOKOM has been operating as a distributor on the Polish market since 1995, representing over 20 reputable companies from around the world, focusing on a range of reagents and equipment dedicated to biological and biomedical sciences. Al-Hobail Medical Office was established in 1987 to work in the field of importing and distributing medicines, medical chemicals, medical equipment and lab supplies to the Saudi market and the GCC tender.

“One of our strategic objectives here at Arquer has been to maximise the potential of our innovative diagnostic technologies by securing high-quality partnerships with businesses around world who not only offer distribution, but also excellent technical and scientific support to our customers,” comments Nadia Whittley, Arquer CEO. “We are extremely excited about the partnerships with BIOKOM and Al-Hobail as they are both highly reputable and experienced distributors in the biomedical field and this represents an important step forward in delivering our non-invasive oncology diagnostic products for these regions.”

 

BIOKOM Diagnostyka Sp. z o.o.

BIOKOM

ul. Wspólna 3

05-090 Janki, Poland

Tel. +48 22 720 71 40

info@biokom.com.pl

www.biokom.com.pl

Al-Hobail Medical Office

KSA – Riyadh – Playa St – Spring Building

PO 61376, Riyadh 11565

Saudi Arabia

Tel: +966 92 000 6647

medical@al-hobail.com

www.al-hobail.com

About ADXBLADDER

ADXBLADDER received its CE Mark on 11th October 201 and was launched at the 37th Société Internationale D’Urologie (SIU) meeting later that month. It is a new non-invasive urine test for bladder cancer which provides a clear cut ‘yes/no’ result within three hours. In a blinded prospective study, 577 patients (318 male and 248 female) attending diagnostic haematuria clinics at six UK centres underwent ADXBLADDER ELISA testing. The results from the ADXBLADDER test were then compared to the current benchmark of combined results from cystoscopy, ultrasound and CT scanning. The results showed the ADXBLADDER test was extremely reliable, demonstrating a sensitivity of 95% for higher risk cancers and a negative predictive value greater than 97%. In addition, the test offers innovative features, such as the result being unaffected by urinary tract infections (UTIs) and utilising the ELISA testing methodology, meaning no requirement for specialist analysis. ADXBLADDER is currently commercialised in UK, France, Italy, Turkey Germany, Spain, Portugal and the Netherlands and Belgium and will be further released to other European countries and worldwide regions in 2018

About Arquer Diagnostics

Arquer Diagnostics (www.arquerdx.com) headquartered in Sunderland, United Kingdom, is a company focused on the development of non-invasive cancer diagnostic tests, based on the MCM5 (minichromosome maintenance protein) platform. Arquer Ltd was launched in 2015, following a strategic decision to put into action the powerful research that had been conducted by a small enterprise, founded in 2005 by Nick Miller-Jones (UroSens). Since then, the company has amassed strong clinical data to support the launch of its first product ADXBLADDER, a bladder cancer diagnostic test, and is running a number of clinical trials to validate many other indications. Arquer is supported by first class international Medical Advisory Boards and together we are aiming at inspiring transformational change in the field of oncology diagnostics.

Contact: Arquer Diagnostics Ltd
T: +44 (0) 191 516 6765
E: info@arquerdx.com
www.arquerdx.com

Kick The Habit This October

Did you know that tobacco is the single biggest preventable cause of cancer, and alcohol is a causal factor in a number of cancers and more than 60 other medical conditions? While these facts alone are alarming, scientists have also proven that the effects of alcohol and tobacco consumption are much worse when used in combination than by themselves. Every October, millions of us up and down the U.K. come together to try and kick these habits, either for the month alone or once and for all.

While quitting smoking and drinking offers significant improvements to your health and your bank balance, you’re also improving the lives of loved ones around you. Statistics show that specialist services and support give you the best chance of giving up your vices successfully, so why not sign up for Stoptober, Go Sober For October, or both! Not only are you taking control of your health, but you’ll be raising much-needed money and awareness for such vital charities.

Stoptober

Stoptober is an initiative from the NHS who understand just how important getting the right support is when attempting to ditch cigarettes for good. Their website is a hub of helpful tools and information, allowing you to create a free personalised quit plan, monitor your progress with the handy Stoptober app, and be motivated by the inspirational success stories of so many others just like you. It’s about finding the right combination of support that really works for you, and Stoptober is the perfect gateway to get you started. More than one in four cancer deaths are caused by smoking and up to two in three long-term smokers will die as a result of their habit. Make a change today.

Go Sober For October

On the other hand, Macmillan Cancer Support also encourage us all to Go Sober For October and raise money for those of us already living with cancer. Once again, support is key, which is why Macmillan promise to help you along your journey when you sign up via their website. As mentioned above, alcohol plays a part in your cancer risk, and an alarming 2.5 million of us in the UK admit to consuming over 14 units on our heaviest drinking days. With that said, alcohol consumption is steadily declining, leaving more of us feeling healthier and energised.

We may be well into October already, but it’s never too late to dive in at the deep end and take part in either of these fantastic campaigns. You can find out more about each via their websites, and encourage your friends and family to do the same so that you can enjoy many more years together. This could be the kickstart you’ve been looking for to take your health into your own hands, so don’t waste another moment!

Biomarkers, Bladder Cancer & ADXBLADDER

We all know just how important it is to detect bladder cancer as early as possible to increase the chances of treatment success and long-term survival, but this is a lot easier said than done; the symptoms of bladder cancer can be vague. The most common and noticeable symptom is blood in your urine, known as haematuria, which should always be investigated – even if it is infrequent and painless. In order to meet the demand for faster, more reliable diagnostic solutions, Arquer Diagnostics looked toward bladder cancer biomarkers for a solution, which led to the development of our innovative MCM5 technology. But what are biomarkers?

Biomarkers

Simply put, when a change occurs within normal biological processes, molecules known as biomarkers are produced and can be measured to help indicate these changes. For this reason, we can use biomarkers to successfully detect and monitor numerous health conditions, such as cancers. Biomarkers manifest in various different ways and can be found in a number of different sample types. In the case of bladder cancer, the MCM5 protein is robustly produced by dividing cells and those preparing to divide in the underlying layers of linings and cavities of certain organs. These proteins are not usually found within bodily fluids unless cancer or certain damage is present, which is why MCM5 proteins make for such excellent bladder cancer biomarkers.

ADXBLADDER

Here at Arquer Diagnostics, drawing upon years of extensive research and development, our experts created ADXBLADDER – a urine-based bladder cancer test that is simple, rapid, and highly reliable. The accuracy of ADXBLADDER is unprecedented, capable of detecting MCM5 proteins that have been shed into the urine as a result of a bladder cancer tumour, with a 95% success rate for aggressive, high-grade tumours. Providing a more accurate diagnostic test versus the current standard of urine cytology was our main objective – meeting a need expressed by patients and practitioners alike. While urine cytology has been used to detect bladder cancer since the 1800’s, this outdated methodology poses numerous issues, the most important of which is a low sensitivity (ability to pick up cancers) and this is why we are currently seeing a growing interest in the development of new urine-based liquid biopsy tests, such as ADXBLADDER. Biomarkers have the potential to replace uncomfortable cystoscopy (where a camera is inserted into the urethra to visually assess the presence of a tumour) in some situations and to aid in the assessment of patients.

It is our hope that we can change the lives of bladder cancer patients around the world with ADXBLADDER, which is already available across Europe and a number of other global regions. Our groundbreaking MCM5 technology is applicable to a number of other cancer types, for which we are developing trials to meet further worldwide healthcare demands by offering more clinically relevant tests in the future. To find out more about Arquer Diagnostics and ADXBLADDER, visit our website.

Arquer Diagnostics completes patient recruitment for MCM5 clinical trial

  • 801 patients recruited for international clinical study to evaluate Arquer’s ELISA-based urine test for bladder cancer
  • Study results will serve to submit for CE marking

Sunderland, UK, 13th March 2017: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for bladder cancer, today announced that it has completed the recruitment of 801 patients for a clinical trial to evaluate the Company’s MCM5 bladder cancer diagnostic.

The results from the study will be used as part of the Company’s application for CE mark approval, ahead of the commercial launch of the MCM5 ELISA for Bladder Cancer, which is planned for Q3 2017. The study is expected to confirm the results obtained in a recent feasibility study, which indicated that the MCM5 ELISA performs well above other non-invasive diagnostic tests currently utilised in the routine diagnosis of bladder cancer, in terms of both specificity and sensitivity.

Continue reading “Arquer Diagnostics completes patient recruitment for MCM5 clinical trial”

Arquer Diagnostics awarded funding under Innovate UK’s Biocatalyst programme

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer

Sunderland, UK, 1st March 2017: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for bladder cancer, today announced that it has been awarded £70,000 funding under Innovate UK’s Biocatalyst programme, to be awarded over a 12 month period, starting 1st March 2017. The funding will be used to support preparations for an international clinical study to evaluate Arquer’s MCM5 ELISA-based non-invasive test for prostate cancer, as the Company expands the application of its technology into a wider range of cancers.

Continue reading “Arquer Diagnostics awarded funding under Innovate UK’s Biocatalyst programme”

Arquer Diagnostics Appoints Nadia Whittley as CEO

Sunderland, UK, 1st December 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for cancer, today announced that it has appointed Nadia Whittley as CEO with immediate effect. With significant experience in strategy, sales and marketing, organisational effectiveness, M&A and fundraising in the small and mid-cap sectors, Nadia’s focus at Arquer will be to execute the commercial launch of the Company’s MCM5-ELISA diagnostic test, and expansion of the technology into a wider range of cancers.
With over 25 years’ experience in the life science sector, Nadia Whittley has an outstanding leadership record of growing revenues and motivating teams spanning several therapeutic areas and across different geographies, including EMEA, Asia Pacific and North America. Most recently Nadia was Partner and Managing Director, Europe, of Tefen Management Consulting, where she was responsible for the design and implementation of a 5-year strategic plan and development of the Life Science Business Unit in EMEA. Previously Nadia was CEO at Alium Medical Ltd, Managing Director Medical Devices EAME at Allergan Inc., Marketing Director EMEA in Interventional Cardiology at Boston Scientific International, and a non-executive Board member at Peptonic Medical AB.

Continue reading “Arquer Diagnostics Appoints Nadia Whittley as CEO”

Arquer Diagnostics and the University of Sunderland collaborate to extend application of cancer diagnostic

Partnership will investigate non-invasive specimen preparation techniques for Arquer’s MCM5-ELISA test in a wider range of cancers

Sunderland, UK, 17 October 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for cancer, today announced that it has signed a collaboration agreement with the University of Sunderland. The partnership aims to investigate non-invasive specimen preparation techniques, which will facilitate the use of Arquer’s MCM5-ELISA test in a wider range of cancers.
Arquer’s MCM5-ELISA is a simple, non-invasive test, which has been developed to accurately diagnose both bladder and prostate cancer. The test works by detecting the presence of minichromosome maintenance complex component 5 (MCM5) protein, a marker for the presence of dividing cancer cells, in urine. MCM proteins are directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. Through the partnership with the University of Sunderland, Faculty of Applied Sciences, Arquer aims to identify the optimal conditions for processing various samples collected using different collection methods to assist in the preparation of a clinical feasibility study in a wider range of cancers.
Continue reading “Arquer Diagnostics and the University of Sunderland collaborate to extend application of cancer diagnostic”

Arquer Diagnostics Appoints Louise Flintoft as Product Manager

Appointment strengthens senior team in preparation for EU regulatory approval and commercial launch of Mcm5-ELISA test

Sunderland, UK, 13 July 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for cancer, today announced the appointment of Louise Flintoft to the post of Product Manager. Louise’s appointment serves to strengthen Arquer’s commercial team in preparation for EU regulatory approval and commercial launch of its Mcm5-ELISA test. Louise will take responsibility for all aspects of product marketing, commercial management and distribution, as well as being a key contributor to future product development and commercialisation.
Continue reading “Arquer Diagnostics Appoints Louise Flintoft as Product Manager”